POS0814 DRUG RETENTION RATE, REASONS FOR DISCONTINUATION AND OUTCOME OF INFLIXIMAB USE IN BEHÇET SYNDROME
Authors: S. N. Esatoglu, B. Tukek, S. S. Taflan, Y. Ozyazgan, D. Ucar, V. Hamuryudan, Y. Ozguler, E. Seyahi, M. Melikoglu, U. Uygunoglu, A. Siva, Z. Kutlubay, I. Fresko, S. Yurdakul, H. Yazici, G. Hatemi
Journal: Annals of the Rheumatic Diseases (2021)

Background: Infliximab (IFX) plays a key role in the management of severe and refractory manifestations of Behçet syndrome (BS). However we had previously shown that its sustained use may be limited due to adverse events and lack of patient compliance (1). Objectives: To assess the retention rate of IFX, adverse events, causes of discontinuation and outcome after cessation of IFX in a larger group of BS patients who were followed in a tertiary center. Methods: The charts of BS patients who were prescribed IFX between 2004 and 2020 were reviewed to determine demographic features, reasons for IFX use, previous and concomitant drugs, IFX duration, reasons for cessation of IFX and time to flare following cessation of IFX. Follow-up was censored on March 2020. Results: A total of 252 patients (195 men, mean age 40±10 years) received IFX for uveitis (n=122), vascular involvement (n=82), parenchymal neurologic involvement (n=32), gastrointestinal involvement (n=11), arthritis (n=10), mucocutaneous involvement (n=4), and secondary amyloidosis (n=1). Ten patients had more than 1 involvement requiring IFX. During a median follow-up of 52 (IQR: 30-88) months, 122 (48%) patients were still receiving IFX for a median period of 33 (IQR: 15-56) months while 130 (52%) patients had discontinued IFX after a median follow-up of 17 (IQR: 7-31) months. Reasons for discontinuation were remission in 25 (19%) patients, adverse events in 39 (30%), lack of efficacy in 23 (18%) (4 primary and 19 secondary), lack of patient compliance in 36 (28%), pregnancy in 4, and preparation for surgery in 3 patients. Adverse events (n=39) that required the cessation of IFX were infusion reaction (n=17), infection (n=7), hepatotoxicity (n=4), malignancy (n=4), palmoplantar psoriasis (n=3), lichen planus (n=1), drug induced lupus (n=1), splenic infarction (n=1), and a decrease in left ventricular ejection fraction (n=1). Among the 25 patients who discontinued IFX due to remission, 5 (20%) had a relapse after 4, 21, 26, 29, 38 and 46 months. The remaining patients did not experience a relapse during a median follow-up of 35 (IQR: 24-68) months. At the end of the follow-up, 2 patients had died due to lung adenocarcinoma during IFX treatment and 3 patients had died 1 year, 3 and 8 years after IFX discontinuation. The causes of death were with right heart failure due to pulmonary hypertension in 1, and severe nervous system involvement in 2 of the patients. Conclusion: Despite its successful use for the management of potentially organ and life-threatening manifestations in more than half of our patients with BS, long term maintenance was not possible in 42%, mainly due to adverse events, lack of patient compliance and inefficacy. Reference: [1]Esatoglu SN, Tukek B, Taflan SS, et al. SAT0258 Drug Retention Rate and Prognosis After Discontinuation of Infliximab in Patients with Behçet Syndrome. Annals of the Rheumatic Diseases 2020;79: 1071-1072. Reasons for infliximab treatment No of patients No (%) of patients who were still receiving infliximab Number (%) of patients who discontinued infliximab Reasons for discontinuation Duration of infliximab use (median (IQR) months ) Eye involvement 122 59 (48) 63 (52) Remission (n=17) Inefficacy (n=10) Lack of patient compliance (n=19) Adverse event (n=12) Others (n)=5) 28 (12.5-52) Vascular involvement 82 40 (49) 42 (51) Remission (n=10) Inefficacy (n=7) Lack of patient compliance (n=12) Adverse event (n=12) Others (n=4) 18.5 (9-33.5) Parenchymal neurologic involvement 32 21 (66) 11 (34) Adverse event (n=8) Inefficacy (n=2) Lack of patient compliance (n=1) 25 (14.5-50) Gastrointestinal involvement 11 4 (36) 7 (64) Remission (n=1) Inefficacy (n=1) Adverse event (n=2) Lack of patient compliance (n=4) 7 (2-17) Joint involvement 10 2 (20) 8 (80) Inefficacy (n=1) Adverse event (n=5) Lack of patient compliance (n=2) 20 (4-35) Mucocutaneous involvement 4 3 1 Inefficacy (n=1) 6, 10, 12, 104 months AA amyloidosis 1 0 1 Inefficacy (n=1) 6 years Disclosure of Interests: None declared